मलेशिया - अंग्रेज़ी - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - desloratadine -

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

physicians total care, inc. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r), pseudoephedrine sulfate (unii: y9dl7qpe6b) (pseudoephedrine - unii:7cuc9ddi9f) - desloratadine 2.5 mg - clarinex-d® 12 hour extended release tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. clarinex-d 12 hour extended release tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see clinical pharmacology (12)] . clarinex-d 12 hour extended release tablets are contraindicated in: - patients with hypersensitivity to any of its ingredients, or to loratadine [see warnings and precautions (5.4) and post-marketing experience (6.2)] - patients with narrow angle glaucoma - patients with urinary retention - patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment [see drug interactions (7.1)] . - patients with severe hypertension or severe coronary artery disease pregnancy category c: there are no adequate and well-controlled stu

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

merck sharp & dohme corp. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r), pseudoephedrine sulfate (unii: y9dl7qpe6b) (pseudoephedrine - unii:7cuc9ddi9f) - desloratadine 2.5 mg - clarinex-d® 12 hour extended release tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. clarinex-d 12 hour extended release tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see clinical pharmacology (12)]. clarinex-d 12 hour extended release tablets are contraindicated in: - patients with hypersensitivity to any of its ingredients, or to loratadine [see warnings and precautions (5.4) and adverse reactions (6.2)] - patients with narrow-angle glaucoma - patients with urinary retention - patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment [see drug interactions (7.1)] - patients with severe hypertension or severe coronary artery disease risk summary the limited available data with clarinex-d 12 hour in pregnant wom

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

bryant ranch prepack - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older. desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions (5.1) and adverse reactions (6.2)]. risk summary   the limited available data with desloratadine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. there are no adequate and well-controlled studies in pregnant women. desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (auc)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (r

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine tablets  are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. desloratadine tablets  are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older. desloratadine tablets  are indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 12 years of age and older. desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions (5.1) and adverse reactions (6.2)]. risk summary the limited available data with desloratadine in pregnant women are not sufficient to inform a drug- associated risk for major birth defects and miscarriage. there are no adequate and well-controlled studies in pregnant women. desloratadine given during organogenesis to pregnant rats

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

a-s medication solutions - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older. desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions (5.1) and adverse reactions (6.2)]. risk summary   the limited available data with desloratadine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. there are no adequate and well-controlled studies in pregnant women. desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (auc)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (r

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - desloratadine - oral solution - 500microgram/1ml

कनाडा - अंग्रेज़ी - Health Canada

pharmascience inc - desloratadine - tablet - 5mg - desloratadine 5mg - second generation antihistamines

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - desloratadine - tablet - 5mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - desloratadine - tablet - 5mg